A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease

16822EASI-PROTKTOpenA Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease1378-0041NCT07064473IndustrialAdultTreatmentIIIOtherPark, JeanMedStar Health and GUMC; Medstar Montgomery Medical CenterMHRI Community Research10905Margot GiannettiMargot GiannettiMargot.Giannetti@medstar.netClinical Research Coordinator 17019Mehrnoosh EmamiMehrnoosh Emamimehrnoosh.emami@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>